Top 50 Europe-based Pharmaceutical Company Selects eResearchTechnology to Provide Enterprise Electronic Data Capture Platform
March 29 2005 - 9:05AM
PR Newswire (US)
Top 50 Europe-based Pharmaceutical Company Selects
eResearchTechnology to Provide Enterprise Electronic Data Capture
Platform Agreement Includes Enterprise License and Maintenance
Services, With Potential to Leverage Trial-based Site Support
Services PHILADELPHIA, March 29 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading
e-research technology and services provider, announced today that
it has entered into an agreement with a top 50 Europe- based
pharmaceutical organization to provide an enterprise electronic
data capture (EDC) license and maintenance services. The Enterprise
EDC license agreement follows several years of partnering between
eRT and the sponsor to deploy EDC studies using the platform under
a subscription agreement. Throughout the process, eRT provided
comprehensive knowledge and technology transfer services to support
institutionalization of EDC Best Practices in areas such as study
design and site support services. "eRT has enjoyed its
collaboration with this thought leading organization for a number
of years, and we are delighted that key executives have elected to
go forward with an enterprise agreement, signaling broad adoption
of EDC for this sponsor across a number of clinical development
programs," said Scott Grisanti, senior vice president of business
development and chief marketing officer at eRT. "Enterprise EDC
adoption is critical to value maximization, and eRT's comprehensive
program of support throughout study implementation and conduct,
were key to this success story." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Report on Forms 10-K filed with the Securities and
Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT:
Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-858-704-5065, for
eResearchTechnology Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles